Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huc-MSC for Psoriasis
NCT03765957Phase 1Unknown
- Sponsor
- Central South University
- Start
- Feb 2019
- Primary completion
- Jul 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human umbilical cord derived mesenchymal stem cells in psoriasis (4 arms), sponsored by Central South University. Primary endpoints: Number of Participants Achieving Psoriasis Area and Severity Index >=75% Improvement at Month 6 and Number of Participants Achieving a Physician Global Assessment of (0, 1) at Month 6. Status: unknown.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03765957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765957.